Halfan Side Effects
Generic name: halofantrine
Note: This document contains side effect information about halofantrine. Some of the dosage forms listed on this page may not apply to the brand name Halfan.
Some side effects of Halfan may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to halofantrine: oral tablet
Along with its needed effects, halofantrine (the active ingredient contained in Halfan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking halofantrine:Less common
- noisy, rattling, or troubled breathing
- Abdominal pain
- chest pain
- convulsions (seizures)
- difficulty in breathing or swallowing
- itching, especially of feet or hands
- pounding heartbeat
- reddening of skin, especially around ears
- swelling of eyes, face or inside of nose
- unusual tiredness or weakness
Some side effects of halofantrine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More Common
- Aches and pain in joints
- frequent urination
- loss of appetite
- skin itching or rash
For Healthcare Professionals
Applies to halofantrine: oral tablet
Higher risk may be associated with larger than recommended doses, previous or concurrent mefloquine treatment, preexisting QT interval prolongation, or concurrent administration of other QT interval-prolonging drugs. Prolonged QTc interval has been reported in up to 81% of adults treated with standard halofantrine (the active ingredient contained in Halfan) doses and in 100% of patients treated with high doses (72 mg/kg). Prolonged QTc interval has been reported in 50% of children and prolonged PR interval has been reported in 38% of children (n=21). Females may have a higher risk of adverse cardiovascular effects.
It has been proposed that halofantrine prolongs repolarization by blocking HERG potassium channels.
Cardiovascular side effects have included QT interval prolongation, torsades de pointes, ventricular arrhythmias, and death. Chest pain and palpitations have been reported less than 1% of patients in clinical trials, and orthostatic hypotension has been reported in less than 1% to 33% of patients. Hypertensive crisis (1/933) and cerebrovascular accident (1/933) have been reported, although causality was not clearly established. Quinidine-like electrocardiographic changes have also been reported.
Gastrointestinal (GI) side effects have included abdominal pain (8.5%), diarrhea (6%), vomiting (4.3%), and nausea (3.4%), although these symptoms may also occur with a malarial infection. Abdominal distention, anorexia, constipation, dyspepsia, and stomatitis have been reported in less than 1% of patients. GI upset has also been reported.
Hematologic side effects have included decreased hematocrit, decreased or increased white blood cells, decreased platelet counts, hemolysis, and hemolytic anemia. These reactions may also occur with a malaria infection.
Hypersensitivity side effects have included allergic and anaphylactic reactions including facial edema and urticaria.
Dermatologic side effects have included pruritus (2.6%) and rash (less than 1%).
Musculoskeletal side effects have included rigors (1.7%), myalgia (1.3%), arthralgia (less than 1%), and back pain (less than 1%).
Nervous system side effects have included dizziness (4.5%) and headache (3%). Asthenia, confusion, convulsions, depression, paresthesia, and sleep disorder have been reported in less than 1% of patients.
Genitourinary side effects have included urinary frequency (less than 1%).
Ocular side effects have included abnormal vision (less than 1%).
Respiratory side effects have included cough (3%). Pulmonary edema has been reported (1/933); however, causality was not determined.
Other side effects have included fatigue, malaise, and tinnitus in less than 1% of patients.
Hepatic side effects have included increased hepatic transaminases, which returned to normal within 2 to 3 weeks.
Renal side effects have included blackwater fever (acute intravascular hemolysis with acute renal failure and hemoglobinuria) requiring hemodialysis patients taking halofantrine (the active ingredient contained in Halfan) for Plasmodium falciparum infections (n=2). Causality was not clearly established. One patient had a positive Coombs test.
More Halfan resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.